Botulinum neurotoxin A for chronic migraine headaches:does it work and how? by Cairns, Brian Edwin & Gazerani, Parisa
   
 
Aalborg Universitet
Botulinum neurotoxin A for chronic migraine headaches
Cairns, Brian Edwin; Gazerani, Parisa
Published in:
Pain Management





Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Cairns, B. E., & Gazerani, P. (2014). Botulinum neurotoxin A for chronic migraine headaches: does it work and
how? Pain Management, 4(6), 377–380. DOI: 10.2217/PMT.14.30
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: April 26, 2017




10.2217/PMT.14.30 © 2014 Future Medicine Ltd
EDITORIAL
Botulinum neurotoxin A for chronic 
migraine headaches: does it work 
and how?
1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, V6T 1Z3, Canada 
2Center for Sensory-Motor Interaction, Department of Health Science & Technology, Faculty of Medicine, Aalborg 
University, Aalborg E, Denmark
*Author for correspondence: Tel.: +1 604 822 7715;  Fax: +1 604 822 3035; brcairns@mail.ubc.ca
KEYWORDS  
• chronic migraine • clinical trials 
• glutamate • headache • muscle 
• neurotoxin • neurotransmitter 
release • nociceptor  • prophylaxis
Does it work?
In 2010, botulinum neurotoxin A 
(BoNTA) was approved to prevent 
headaches in adult patients with chronic 
migraine. The approval was based on the 
outcomes of two multicenter clinical trials 
(PREEMPT 1 & 2) that tested the efficacy 
and safety of BoNTA [1,2]. In PREEMPT 1, 
the primary efficacy end point, which was 
the average number of headache episodes, 
was similar for BoNTA and placebo. 
However, the number of headache days 
was reduced in the BoNTA group [1]. In 
the PREEMPT 2, the primary efficacy end 
point was the mean change from baseline 
in headache days from 21–24 weeks post-
treatment and was found to be significantly 
lower in the BoNTA treatment group [2]. 
A planned pooled analysis of all patients 
included in PREEMPT 1 and 2 showed 
significant improvements in all secondary 
end points with BoNTA compared with 
placebo [3]. BoNTA was well tolerated, but 
adverse events including neck pain, muscle 
weakness, headache and migraine led to 
withdrawal of a small number of patients 
in these studies. However, a high placebo 
effect combined with concerns about 
inability to blind patients to the paralytic 
effects of BoNTA and the heterogeneity of 
the study participants in terms of headache 
diagnosis, have lead to lingering questions 
about the efficacy of BoNTA for migraine 
prophylaxis.
A recent high quality meta-analysis to 
assess the effects of BoNTA for prophy-
lactic treatment of headaches that included 
27 placebo-controlled and four active-
controlled trials has addressed questions 
about efficacy [4]. This analysis found that 
BoNTA injections significantly reduced 
the frequency of chronic daily headache 
and chronic migraine when compared with 
placebo, but did not have any significant 
effect on episodic migraines or chronic 
tension headaches. However, patients who 
received BoNTA had more adverse events 
than had been previously recognized and 
a large placebo effect was identified. Thus, 
while BoNTA appears to be effective for 
chronic migraine and chronic daily head-
ache, more evidence-based data is needed 
to provide reliable information for or 
against the use of BoNTA in other types 
of headaches, which include cervicogenic 
or cluster headaches [5].
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The findings of these studies provide insight 
into which headache types might respond to 
BoNTA, but definitive predictors of individ-
ual patient response have not yet been identi-
fied. A single study reported a higher response 
rate to BoTNA when migraine patients who 
reported ‘imploding’ headaches, where pain is 
perceived as emanating from external pressure 
and includes a significant ocular component, 
were compared with those reporting ‘explod-
ing’ headache, where pain is perceived to come 
from inside the head [6]. Chronic migraine is also 
more prevalent in women, but whether response 
to BoNTA differs in a sex-related manner is not 
known. Migraine aura might also be a predic-
tor of response. While it is clear that additional 
work is needed to improve identification of best 
candidates for, and optimal route, location and 
dose of administration of BoNTA [7], there is 
general agreement that both fixed-site/fixed-dose 
and ‘follow-the-pain’ paradigms are effective 
for headache prophylaxis [5]. Future clinical 
trials may also reveal whether other botulinum 
neurotoxins (e.g., BoNTB) have comparable 
safety and efficacy profiles to BoNTA.
How does it work?
BoNTA is made up of a light chain, which 
contains a zinc protease component, connected 
by a disulfide bridge to a heavy chain that facil-
itates uptake of the toxin into the peripheral 
endings of nerve fibers [8]. The toxin rapidly 
enters the axon terminal by binding to receptors 
expressed on the membrane [8,9]. In the cytosol, 
the disulfide bond between the heavy and light 
chain is broken and the two chains separate. 
The light chain of BoNTA binds to and cleaves 
SNAP-25, part of the structure responsible for 
vesicular docking to the membrane that permits 
neurotransmitter release [10]. This results in a 
long lasting, reversible inhibition of neurotrans-
mitter release from the terminal due to the stabil-
ity of the BoNTA light chain in the cytosol [11]. 
As a result, injected BoNTA blocks neurotrans-
mission from motor and autonomic nerve termi-
nals, leading to muscle paralysis and inhibition 
of autonomic function, respectively [12]. It also 
reduces the sensitivity of sensory afferent fibers 
to noxious stimulation and inhibits neurogenic 
inflammation.
For migraine prophylaxis, BoNTA is 
injected into craniofacial muscles includ-
ing the temporalis muscle. BoNTA has been 
found to decrease the mechanical sensitivity 
of nociceptors that innervate these muscles as 
well as the underlying periosteum, within 3 h 
of injection [13,14]. One important determinant 
of muscle nociceptor mechanical sensitivity is 
the concentration of the amino acid glutamate 
in the interstitial space [15]. Intramuscularly 
injected BoNTA has been shown to significantly 
decrease muscle interstitial glutamate concentra-
tion [14,15]. BoNTA may also block the normal 
cycling of receptors (e.g., glutamate receptors) 
from inside the axon to the axon membrane sur-
face [11]. Through these mechanisms, BoNTA 
would directly attenuate nociceptive input 
from the muscles. It has recently been found 
that some nociceptors that innervate the dura, 
which is proposed to be a principal source of 
pain in migraines, have extracranial projections 
to the periosteum underlying the temporalis 
muscle [13,16]. Thus, it is possible that injection of 
BoNTA into the temporalis muscle also acts on 
these extracranial branches of dural nociceptors 
to lower nociceptive input [13].
It has also been proposed that BoNTA 
injected peripherally can access the CNS where 
it could act to decrease synaptic transmission in 
pain pathways. It has been known for some time 
that injected radiolabeled BoNTA can be trans-
ported through sensory (and motor) axons as 
far as the CNS [9,11]. Indirect evidence based on 
immunohistochemical detection of the cleaved 
form of SNAP-25 has recently suggested that 
functional BoNTA not only reaches the central 
endings of nociceptor axons but may act on neu-
rons in the CNS [11]. If confirmed, this evidence 
would suggest that part of the analgesic action 
of BoNTA is due to central mechanisms [9,11].
In addition to preclinical work, the analge-
sic effect of BoNTA in experimental models of 
pain in healthy humans has also been investi-
gated. BoNTA injection into the human tem-
poralis muscle was found to significantly reduce 
glutamate-evoked pain and vasomotor responses 
beginning 3 h after injection and lasting for at 
least 7 days [17]. These findings suggest a relatively 
short onset of analgesic effect when BoNTA is 
injected intramuscularly. It has subsequently 
been shown that BoNTA decreased pain and 
cutaneous glutamate release provoked by cap-
saicin plus mild heat application to the volar 
forearm, which suggests that attenuation of tissue 
glutamate concentrations also contributes to the 
mechanisms of BoNTA analgesia in humans [18].
So, why do these actions of BoNTA decrease 
migraine headache duration and severity? It 
“It has also been 
proposed that 
botulinum neurotoxin A 
injected peripherally 
can access the CNS 
where it could act to 
decrease synaptic 
transmission in pain 
pathways.”
379
Botulinum neurotoxin A for chronic migraine headache EDitORial
future science group www.futuremedicine.com
is thought that sustained input from tender 
craniofacial muscles increases the sensitivity of 
trigeminal sensory neurons in the brainstem 
and activates non-neuronal glial cells to con-
tribute to central sensitization; a state of pain 
hypersensitivity. BoNTA, through its proposed 
peripheral and central mechanisms, decreases 
central sensitization and this raises the threshold 
for headache initiation [10]. Evidence in support 
of this concept comes from reports that single 
local anesthetic nerve blocks or even trigger 
point injections, which provide comparatively 
short periods of analgesia, also appear to pro-
vide long lasting relief from headache in some 
migraine patients [19]. It is possible that the quick 
onset of muscle analgesia after BoNTA injec-
tion may be as, or even more, important than 
a long duration of action in terms of decreas-
ing headache frequency. Based on this mecha-
nism, the variability in effectiveness of BoNTA 
to decrease headache frequency would not be 
due to a failure of BoNTA to produce muscle 
analgesia per se, but rather to the fact that in 
certain migraine sufferers, mechanisms other 
than sustained painful input from craniofacial 
muscles are responsible for maintaining central 
sensitization. This may explain the observation 
that BoNTA is more effective at preventing 
‘imploding’ headaches, which are proposed to 
be generated by extracranial pain input. It may 
also explain why subcutaneous injections of 
BoNTA have also been reported to be effective 
for headache prophylaxis in certain patients.
Research is currently underway to produce 
the next generation of botulinum neurotoxins 
that will be engineered for increased duration 
of action and improved proteolytic activity. In 
addition, toxin formulations and novel meth-
ods of toxin delivery (e.g., topical) are being 
investigated as a way to improve efficacy and 
safety. One interesting direction has involved the 
creation of a composite protein of the BoNTE 
protease moiety with BoNTA to produce a 
toxin that has a more rapid onset of effect, like 
BoNTE, but lasts six-times longer than this 
short acting neurotoxin. In a related approach, 
substance P has been conjugated to the light 
chain of BoNTA. The conjugated protein was 
endocytosed by trigeminal ganglion neurons 
in culture and retained its protease activity 
against SNAP-25  [20]. This approach could be 
used to selectively target BoNTA to nociceptors 
and could one day help answer whether muscle 
paralysis is important for BoNTA’s prophylac-
tic effect against migraine. The ultimate goal 
is to introduce selective, specific and potent 
botulinum neurotoxin products to yield unique 
antinociceptive activity where it is needed.
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